Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Infinity Pharmaceuti (INFI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 96,826
  • Shares Outstanding, K 50,430
  • Annual Sales, $ 18,720 K
  • Annual Income, $ -30,100 K
  • 36-Month Beta 2.33
  • Price/Sales 5.31
  • Price/Cash Flow 0.00
  • Price/Book 1.19

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.83 +7.10%
on 04/13/17
3.60 -45.56%
on 04/03/17
-1.34 (-40.61%)
since 03/24/17
3-Month
1.83 +7.10%
on 04/13/17
3.84 -48.96%
on 03/02/17
-0.10 (-4.85%)
since 01/24/17
52-Week
0.84 +133.33%
on 11/04/16
6.63 -70.44%
on 04/25/16
-4.59 (-70.08%)
since 04/22/16

Most Recent Stories

More News
AbbVie (ABBV) Presents Positive Data on HCV Combination Drug

AbbVie Inc. (ABBV) announced that data from two phase III studies, EXPEDITION-1 and ENDURANCE-3, evaluating its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P) for all genotypes...

ENTA : 31.03 (+1.31%)
GRFS : 20.26 (+1.55%)
INFI : 1.96 (+2.08%)
ABBV : 64.66 (+1.32%)
Nivalis' (NVLS) Shares Down After Merger Deal with Alpine

The announcement of Nivalis Therapeutics, Inc.'s (NVLS) merger agreement with a privately-held biotechnology company, Alpine Immune Sciences, Inc. failed to excite investors.

CORT : 9.20 (+0.99%)
GRFS : 20.26 (+1.55%)
INFI : 1.96 (+2.08%)
NVLS : 2.10 (-7.08%)
Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III

Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Hakko Kirin Co., Ltd announced positive data from a phase III study evaluating its pipeline candidate burosumab (KRN23) in adults with...

HSKA : 107.40 (+2.12%)
GALE : 0.58 (unch)
RARE : 61.31 (+1.22%)
INFI : 1.96 (+2.08%)
Why Is Infinity (INFI) Down 37.4% Since the Last Earnings Report?

Infinity (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

INFI : 1.96 (+2.08%)
AMAG Files for FDA Approval of Subcutaneous Form of Makena

AMAG Pharmaceuticals, Inc. (AMAG) announced the submission of a supplemental New Drug Application (sNDA) to the FDA for the subcutaneous auto-injector form of its marketed drug Makena in the U.S.

CORT : 9.20 (+0.99%)
GRFS : 20.26 (+1.55%)
INFI : 1.96 (+2.08%)
AMAG : 23.20 (+3.57%)
Infinity Pharmaceuticals (INFI) Looks Good: Stock Jumps 19%

Infinity Pharmaceuticals, Inc. (INFI) shares rose over 19% in the last trading session.

GRFS : 20.26 (+1.55%)
INFI : 1.96 (+2.08%)
Today's Research Reports on Biotech Stocks to Watch: Cleveland BioLabs and Infinity Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / April 18, 2017 / The volatile Biotech Industry has continued to be home to some of the largest gainers on the market in 2017. President Trump's pledge for a faster FDA approval...

CBLI : 3.94 (-1.50%)
INFI : 1.96 (+2.08%)
Bio-Path Holdings (BPTH) Looks Good: Stock Moves 13% Higher

Bio-Path Holdings, Inc. (BPTH) shares rose over 13% in the last trading session.

INFI : 1.96 (+2.08%)
BPTH : 0.71 (+4.41%)
Should You Retain Universal Health (UHS) Stock in Portfolio?

Universal Health Services, Inc. (UHS) stock has gained 9% in last three months, outperforming the Zacks Hospitals industry's increase of 7.6%.

UHS : 120.90 (+1.73%)
INFI : 1.96 (+2.08%)
INGN : 80.92 (+2.20%)
UNH : 172.33 (+0.68%)
Ultragenyx's (RARE) XLH Drug Positive in Phase II Study

Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Kirin International plc recently announced positive 64-week data from a pediatric phase II study, evaluating its investigational candidate...

HSKA : 107.40 (+2.12%)
GALE : 0.58 (unch)
RARE : 61.31 (+1.22%)
INFI : 1.96 (+2.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Infinity Pharmaceuticals, Inc. is an innovative cancer drug discovery and development company that is seeking to leverage its strength in small molecule drug technologies to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions.

See More

Support & Resistance

2nd Resistance Point 2.06
1st Resistance Point 2.01
Last Price 1.96
1st Support Level 1.89
2nd Support Level 1.82

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.